AHPA keeps members and the industry informed of recent news and developments that impact the trade through email alerts. Subscribe to news as it happens or a weekly summary of all alerts.
View recent alerts:
Subscribe to AHPA Updates to stay informed about the latest AHPA news and resources.
Published: Wednesday, June 10, 2020
This free webinar provides practical information on how best to resume post-quarantine business operations while protecting your workforce. Learn what personal protective equipment and workspace adaptations should be implemented and how to manage ongoing business risks and liabilities. Additionally, hear from experts about how to be proactive and search for, and then correct, workplace conditions that could increase risk of COVID-19 infections.
The COVID-19 pandemic caused by the novel coronavirus is likely the most significant public health emergency we have ever faced, both individually and as the health-promoting herbal products industry. As more states and localities across the country announce plans to re-open, businesses must face the question of how to do so as safely, efficiently, and responsibly as possible. What exactly does this new way of conducting business look like for your company? Should your business take a staggered approach to bringing employees back into the workplace based on individual employee factors? Should management require or at least permit remote working indefinitely, or will split-shifts adequately allow employees to maintain social distancing? With safety being a primary factor, what measures are employers implementing to ensure employees are returning to a safe workplace environment?
With the U.S. Food & Drug Administration (FDA) temporarily postponing all routine surveillance inspections of domestic and foreign facilities due to ongoing concerns about the pandemic, how has the Agency been able to maintain oversight over domestic and foreign manufacturers and imported products using alternative tools and methods? In the short term, FDA has focused instead on only “mission critical” domestic inspections (e.g., those related to a recall or a foodborne illness outbreak). What is FDA’s timeline to resume these inspections?
Executive Vice President, General Counsel and Head of Global Regulatory Affairs
Vice President of Quality, Regulatory & Government Affairs
Will Woodlee, Esq.
Kleinfeld, Kaplan and Becker, LLP
AHPA General Counsel
2020 Annual Fund Sponsors
AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.